Articles by Alicia Morgans, MD, MPH
In this episode, “Preserving Quality of Life in Metastatic Castration-Sensitive Prostate Cancer,” the expert faculty explore how cognitive function, independence, and patient priorities influence treatment selection for metastatic castration-sensitive prostate cancer (mCSPC). Through the case of a 74-year-old man with low-volume metastatic disease, mild cognitive impairment, and a strong desire to maintain an active lifestyle, the panel examines the importance of treating the whole patient rather than focusing solely on disease characteristics.
Welcome back to another Urology Times Virtual Tumor Board series. In this episode titled, “Navigating Comorbidities and Treatment Decisions in Metastatic Castration-Sensitive Prostate Cancer,” expert faculty discuss a patient with advanced prostate cancer whose management highlights the importance of individualized treatment decisions that extend beyond tumor characteristics alone.
Alicia K. Morgans, MD, MPH, discusses key findings from the ARACOG study, assessing cognitive outcomes between patients who received darolutamide vs those who received enzalutamide for advanced prostate cancer.
A real-world analysis found that PSADT was undocumented in most patients with high-risk biochemical recurrence of prostate cancer, potentially delaying treatment initiation and underestimating progression risk.
Alicia Morgans, MD, MPH, shares findings from a real-world study assessing darolutamide or abiraterone in combination with ADT plus docetaxel for mHSPC.
Practical Advice for Managing Advanced Prostate Cancer Care
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO Discover essential strategies for managing advanced prostate cancer, including team collaboration, systematic documentation, and patient care best practices.
Balancing Patient Preference and Access Challenges in Oral vs Injectable ADT in Prostate Cancer
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO Healthcare professionals discuss the growing preference for oral hormone therapy over injectables, emphasizing patient control and comfort in treatment choices.
Cardiovascular Risk and ADT Use in Prostate Cancer and Real-World Experience
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO Experts discuss the cardiovascular risks associated with androgen deprivation therapy, comparing relugolix and leuprolide's impact on coronary plaque formation.
Workflow in Advanced Prostate Cancer Care
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO Healthcare professionals discuss the challenges of staff turnover and the importance of communication and systematic notes to ensure patient safety.
Guideline-Based Management of Advanced Prostate Cancer
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO Oncologists discuss the importance of guidelines like NCCN and ASCO for navigating cancer treatment complexities and insurance challenges.
The Role of Pharmacy in Multidisciplinary Management of Oral ADT in Prostate Cancer
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO Health care professionals discuss the vital role of pharmacy teams in managing complex patient care, emphasizing collaboration and medication safety.
Ongoing ADT Monitoring and Treatment Adjustments in Prostate Cancer
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO Urologists discuss the importance of monitoring cardiovascular health in patients undergoing androgen deprivation therapy for prostate cancer.
Reducing Cardiovascular Risk Associated with ADT in mCSPC
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO Healthcare professionals discuss strategies to manage cardiovascular risks in cancer patients, emphasizing weight control, exercise, and collaboration with primary care.
Patient Conversations When Initiating ADT for Prostate Cancer
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO Healthcare professionals discuss the importance of addressing quality of life and exercise for patients starting androgen deprivation therapy.
Treatment Patterns in Advanced Prostate Cancer from Monotherapy to Treatment Intensification
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO Recent trends show a significant increase in the use of combination therapies for advanced cancer, highlighting the need for ongoing education and adaptation.
Interpreting PSMA PET Imaging in Prostate Cancer
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO Experts discuss the complexities of advanced imaging in cancer diagnosis, highlighting challenges with PET scans and the importance of accurate interpretation.
Strategic Use of ADT in mCSPC From Selection to Escalation
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO In this episode, ‘Strategic Use of ADT in mCSPC From Selection to Escalation,’ the multidisciplinary panelists explore the following questions:
With multiple generations of ADT now available in advanced prostate cancer, including oral and injectable options, how do you determine which patients are appropriate candidates for which formulation of ADT?
When selecting ADT as the backbone for doublet therapy in metastatic castration-sensitive prostate cancer (mCSPC), in which patients do you prefer the oral versus the injectable option?
Which androgen receptor pathway inhibitor (ARPI) do you initiate first? Please explain your rationale.
In mCSPC, how do you decide when to escalate from ADT–ARPI doublet to triplet therapy, and what patient or disease factors most influence that decision?
How do you weigh potential benefits against added toxicity and contraindications?
How does cumulative toxicity influence your willingness to escalate therapy or modify treatment plans?
Treatment Selection in Advanced Prostate Cancer
ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO Welcome back to another Urology Times Peer Exchange series. In this episode titled, ‘Treatment Selection in Advanced Prostate Cancer’, Drs. Paul Sieber, Alicia Morgans, Neeraj Agarwal, and Chad Ritch discussed the following question:
When developing treatment plans for prostate cancer, what factors influence treatment selection?
Explore the evolving landscape of immunotherapy in prostate cancer, focusing on personalized treatments and innovative combination strategies.
Explore the evolving landscape of prostate cancer treatment, focusing on personalized immunotherapy and effective patient management strategies.
Experts discuss the importance and limitations of real-world evidence in assessing cardiovascular risks associated with ARPIs, emphasizing the need for critical analysis.
Experts discuss the importance of managing cardiovascular health and bone health in prostate cancer treatment, emphasizing real-world data and patient care strategies.
Long-term data on sipuleucel-T reveal significant survival benefits, emphasizing the importance of multiple lines of therapy in patient outcomes.
Experts discuss the importance of early treatment with Provenge for prostate cancer, highlighting patient demographics and response variability.
Explore the complexities of treating mCRPC with personalized immunotherapies, addressing comorbidities and patient response challenges.
Healthcare professionals discuss adapting treatment guidelines based on genomic testing, emphasizing early detection and personalized care for high-risk patients.
Panelists discuss how the recent FDA approval of darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC) expands treatment options, offering improved tolerability with lower fatigue rates and fewer central nervous system adverse effects than other androgen pathway inhibitors, while exploring considerations for patient selection, trial design interpretation, and the evolving role of real-world evidence in clinical decision-making.
Panelists discuss how the recent FDA approval of darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC) expands treatment options, offering improved tolerability with lower fatigue rates and fewer central nervous system adverse effects than other androgen pathway inhibitors, while exploring considerations for patient selection, trial design interpretation, and the evolving role of real-world evidence in clinical decision-making.
The experts discuss how recent therapeutic advances and trial data are reshaping standard care in advanced prostate cancer.
Alicia Morgans, MD, MPH, and Paul Sieber, MD, introduce the discussion, outlining goals to connect evolving mCRPC research with personalized immunotherapy practice.
